Mass Spectrometry for Identification, Monitoring, and Minimal Residual Disease Detection of M-Proteins

Area of Science:

• Clinical Chemistry
• Analytical Chemistry
• Hematology

Background:

• Monoclonal gammopathies (MGs) involve plasma cell disorders characterized by monoclonal immunoglobulin (M-protein) production.
• M-protein detection and quantification are crucial for diagnosing and monitoring MGs.
• Current diagnostic methods face challenges with therapeutic antibody interference and the need for higher sensitivity to detect minimal residual disease.

Purpose of the Study:

• To review recent mass spectrometry (MS) methods for M-protein detection, characterization, and quantification.
• To discuss the clinical utility, advantages, and disadvantages of MS-based M-protein diagnostics.
• To evaluate the impact of MS techniques on managing patients with MGs.

Main Methods:

• Mass spectrometry (MS) enables accurate mass measurements and targeted peptide fragment analysis.
• MS-based methods provide analytically sensitive measurement of patient-specific M-proteins.
• This review synthesizes recent literature on MS applications in M-protein diagnostics.

Main Results:

• MS offers superior sensitivity and specificity for M-protein analysis compared to traditional methods.
• MS can overcome interferences from therapeutic monoclonal antibodies.
• MS facilitates precise quantification for minimal residual disease monitoring.

Conclusions:

• Mass spectrometry represents a significant advancement in the diagnosis and monitoring of monoclonal gammopathies.
• MS-based methods are poised to enhance patient management by providing more accurate and sensitive M-protein assessment.
• Further integration of MS into routine clinical practice is expected to improve outcomes for patients with MGs.